- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00142623
Tailored Videos to Reduce Tobacco Smoke Exposure Among Pregnant Women and Newborns (ETS)
Reducing ETS Exposure of Pregnant Women and Newborns
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND:
The Healthy People 2010 Objectives address the importance of smoking cessation during pregnancy and the importance of reducing ETS exposure among children and adults. This study will use a new combination of existing technologies to maximize the appropriateness of prenatal and postpartum education concerning ETS exposure in an innovative, inexpensive, and widely applicable approach. The use of tailored DVDs is practical, feasible, and inexpensive enough to be attractive to clinics serving low-income and minority women. A large number of video segments will be produced utilizing live actors, animation, and word slates. About 10 segments will be computer-selected for the videos for each woman based on her responses to four self-assessments. No studies to date have included multiple doses of tailored video education, or used DVDs in this way.
DESIGN NARRATIVE:
This two-arm randomized study is designed to develop and evaluate the efficacy of five tailored DVDs in reducing exposure to ETS among low-income pregnant/postpartum women. The overall purposes of the study are 1) to develop an innovative intervention (tailored "take-home" DVDs) to help pregnant women maximize their pregnancy outcome and their new infant's health through reduction in exposure to ETS and 2) to study the feasibility and efficacy of this intervention compared with a usual care group. This innovative technology will be field tested in collaboration with six prenatal clinics that serve primarily low-income, African American, Latina, and minority women to address two specific aims. Specific aim 1: To test the efficacy of tailored video (TV) versus usual care (UC) approaches in terms of reducing the ETS exposure among fetuses of nonsmoking, low-income women during pregnancy (assessed at 34 weeks gestation using saliva cotinine concentration and ETS self-report) and among infants (as measured by saliva cotinine concentration and mothers' self-reports at 6 months postpartum). Specific aim 2: To test the efficacy of TV versus UC approaches in terms of reducing the exposure of the fetuses of low-income, smoking women to tobacco smoke during pregnancy (assessed at 34 weeks gestation using saliva cotinine concentrations of the pregnant women and smoking and ETS self-reports) and to their infants (as measured by saliva cotinine concentration from the infant at 6 months postpartum and self-reports of infant exposure by the new mothers). Because of the lack of data on reducing ETS exposure amongst low-income and minority women, intensive formative and extensive process evaluation components are included.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Thomas M. Lasater, PhD
- Phone Number: 401-863-6550
- Email: Thomas_Lasater@Brown.edu
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Recruiting
- Brown University
-
Contact:
- Thomas M. Lasater, PhD
- Phone Number: 401-793-8316
- Email: THOMAS_LASATER@BROWN.EDU
-
Principal Investigator:
- Thomas M. Lasater, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women who attend their first prenatal visit by 16 weeks gestation
- Women exposed to tobacco smoke daily
Exclusion Criteria:
- Women expecting complications or multiple births
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: 2
Usual care
|
|
Experimental: 1
Use of five tailored "take-home" DVDs aimed at reducing exposure to ETS
|
Five DVDs aimed at reducing exposure to ETS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Saliva cotinine concentration of mother
Time Frame: Measured at 34 weeks gestation
|
Measured at 34 weeks gestation
|
ETS self-report
Time Frame: Measured at 34 weeks gestation and 6 months postpartum
|
Measured at 34 weeks gestation and 6 months postpartum
|
ETS exposure of infant by self-report of mother
Time Frame: Measured at 6 months postpartum
|
Measured at 6 months postpartum
|
Salvia cotinine concentration of infant
Time Frame: Measured at 6 months postpartum
|
Measured at 6 months postpartum
|
Collaborators and Investigators
Investigators
- Principal Investigator: Patricia M. Risica, DrPH, Brown University
- Principal Investigator: Thomas M. Lasater, PhD, Brown University
- Principal Investigator: Maureen Phipps, MD, Brown University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 249
- R01HL070947 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
National Taiwan University HospitalRecruitingValve Heart DiseaseTaiwan
Clinical Trials on Tailored DVDs
-
Posit Science CorporationCompleted
-
Posit Science CorporationMayo Clinic; University of Southern CaliforniaCompleted
-
Posit Science CorporationCompleted
-
Abramson Cancer Center at Penn MedicineUniversity of FloridaRecruitingCommunication Research | Adolescent Behavior | VapingUnited States
-
Arizona State UniversityMayo Clinic; University of ArizonaCompletedColorectal CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Massachusetts General Hospital; Fox Chase Cancer... and other collaboratorsCompletedCancer | Colorectal | Intervention | ScreeningUnited States
-
University of California, San DiegoNational Institute of Nursing Research (NINR)CompletedInactivityUnited States
-
Johns Hopkins Bloomberg School of Public HealthCompleted
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); Dana-Farber Cancer Institute; Stanford University and other collaboratorsCompletedCigarette Smoking BehaviorUnited States
-
University of NebraskaNational Institute of Nursing Research (NINR)CompletedPre-HypertensionUnited States